Recent Updates
Recently added Catalysts
RLAY Neutral Sentiment

Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Thursday, February 16, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter a
Price reaction · baseline $18.37 (2023-02-15 close) · hit after-hours · clean, no other RLAY news in the window
day 0 close · peak
-5%
day 1
+0.4%
day 3
-3.6%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+284%
120-day peak, hindsight
Typical move
11.8%
average across 6 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
RLY-8161
Phase 1 · Advanced NRAS-Mutant Melanoma

Full Press Release Details

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2022 financial results and corporate highlights after the close of market on Thursday, February 23, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release.
About Relay Therapeutics

Frequently Asked Questions

What is Relay Therapeutics?

Relay Therapeutics is a biopharmaceutical company focused on innovative therapies.

How can I contact Relay Therapeutics?

You can contact Relay Therapeutics through Caroline Glen at 617-370-8837.

Who handles media inquiries for Relay?

Dan Budwick is the media contact for Relay Therapeutics.

What is the media contact's phone number?

Dan Budwick can be reached at 973-271-6085.

What is Caroline Glen's email address?

Caroline Glen's email is cglen@relaytx.com.

ShareAdd on Google
Tags: RLAY Viatris Investor Conferences Healthcare Relay Therapeutics 2022 results financial announcement corporate highlights
Last updated: Feb 16, 2023

Biotech snapshot

Cash runway
$911M liquidity · $18M/mo burn
~50 mo
Minimal dilution risk
Lead asset
RLY-8161Phase 1
Advanced NRAS-Mutant Melanoma →

Catalyst track record

+284%
best trade around RLAY's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RLAY.

See every catalyst's timing & PoA →